Nasdaq:ACRS
Aclaris Therapeutics, Inc.
A Nasdaq-listed biotech firm specializing in proprietary antibody-drug conjugate therapies for solid tumor oncology.
Key Metrics
Investment Thesis
Bull Case
Investors may consider ACRS for exposure to a novel antibody-drug conjugate platform in the high-growth oncology sector with potential for significant value creation upon successful clinical trials. The company's ability to generate positive cash flow from investing activities suggests strategic asset management that could support future financing needs. Potential partnership announcements or regulatory approvals could act as catalysts for stock appreciation.
Bear Case
The sustained multi-year revenue decline and deepening losses of $64.9M indicate fundamental business model challenges that could deplete the company's cash reserves quickly. High operating expenses of $82.1M coupled with minimal gross profit margins pose a significant threat to long-term sustainability without substantial external funding. Investors should be wary of the risk of dilution through equity issuance given the severe retained earnings deficit and negative net income trends.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary oncology therapies, specifically targeting solid tumors with its proprietary antibody-drug conjugate platform. The company serves the global healthcare market by partnering with pharmaceutical entities to advance its pipeline candidates through clinical trials toward regulatory approval. Key revenue drivers include collaboration agreements and milestone payments related to its drug discovery and development programs.
Analysis
Management Discussion
Despite a substantial cash flow from investing of $48.4M primarily driven by marketable security proceeds, the company recorded a net loss of $64.9M and operating profit of -$76.4M, reflecting intense investment in its research and development pipeline. Revenue contraction to $7.8M indicates potential challenges in sustaining collaboration payments or licensing deals without new commercial milestones. The balance sheet remains critical with cash equivalents at $20.0M against total liabilities of $57.4M, necessitating continued capital raising efforts.
Industry Overview
The biotechnology industry is characterized by high R&D costs, long development cycles, and regulatory hurdles before products reach market. Oncology therapeutics represent a massive global market with increasing demand for innovative treatments against solid tumors. Companies must secure strategic partnerships or successful clinical outcomes to achieve commercial viability in this competitive landscape.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $29.8M | $31.2M | $18.7M | $7.8M |
| Cost of Revenue | $4.0M | $3.4M | $2.8M | $2.1M |
| Gross Profit | $25.7M | $27.8M | $15.9M | $5.7M |
| Operating Expenses | $115.6M | $125.2M | $157.9M | $82.1M |
| Operating Income | $-89.9M | $-97.4M | $-141.9M | $-76.4M |
| R&D | $77.8M | $98.4M | $33.6M | $52.6M |
| G&A | $25.1M | $32.4M | $22.2M | $22.0M |
| Stock-Based Comp | $15.0M | $20.5M | $10.9M | $12.4M |
| D&A | $797.0K | $863.0K | $807.0K | $454.0K |
| Depreciation | $700.0K | $800.0K | $700.0K | — |
| Amortization | $75.0K | $75.0K | — | — |
| Other OpEx | $12.6M | $-5.6M | $102.1M | $7.5M |
| Non-Operating Income | $2.9M | $8.5M | $9.9M | $11.5M |
| Interest Income | — | — | $8.0M | $7.6M |
| Pre-Tax Income | $-86.9M | $-88.8M | $-132.1M | $-64.9M |
| Income Tax | $0 | $-367.0K | $0 | $0 |
| Continuing Ops | $-86.9M | $-88.5M | $-132.1M | $-64.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-86.9M | $-88.5M | $-132.1M | $-64.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-86.9M | $-88.5M | $-132.1M | $-64.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $231.6M | $128.9M | $126.0M | $96.3M |
| Cash & Equivalents | $45.3M | $39.9M | $24.6M | $20.0M |
| Accounts Receivable | $484.0K | $298.0K | $318.0K | — |
| Prepaid Expenses | $13.5M | $9.5M | $12.0M | — |
| Other Current Assets | $172.3M | $79.2M | $89.0M | $76.4M |
| Long-Term Assets | $23.0M | $68.5M | $94.4M | $64.1M |
| PP&E (Net) | $1.1M | $1.6M | $1.0M | $761.0K |
| Intangibles | $7.0M | $269.0K | — | — |
| Other LT Assets | $15.0M | $66.7M | $93.4M | $63.4M |
| Total Assets | $254.6M | $197.4M | $220.3M | $160.5M |
| Current Liabilities | $21.9M | $31.0M | $31.6M | $28.6M |
| Accounts Payable | $10.4M | $8.9M | $4.7M | $13.2M |
| Current Leases | $684.0K | $426.0K | $481.0K | $551.0K |
| Deferred Revenue | — | — | $3.9M | $3.9M |
| Other Current Liab | $2.2M | $2.2M | $2.2M | $2.2M |
| Long-Term Liabilities | $35.0M | $9.3M | $33.2M | $28.7M |
| LT Operating Leases | $1.6M | $3.1M | $2.1M | $1.6M |
| Other LT Liab | $33.5M | $6.2M | $11.0M | $11.0M |
| Total Liabilities | $57.0M | $40.2M | $64.8M | $57.4M |
| Shareholders' Equity | $197.6M | $157.2M | $155.6M | $103.1M |
| Paid-In Capital | $880.8M | $928.1M | $1.06B | $1.07B |
| Retained Earnings | $-682.3M | $-770.8M | $-902.9M | $-967.8M |
| AOCI | $-897.0K | $-106.0K | $97.0K | $610.0K |
| Total L&E | $254.6M | $197.4M | $220.3M | $160.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-86.9M | $-88.5M | $-132.1M | $-64.9M |
| Non-Cash Adjustments | $16.2M | $-1.5M | $91.3M | $21.3M |
| Working Capital Changes | $3.1M | $11.6M | $20.7M | $-3.5M |
| Cash from Operations | $-67.6M | $-78.3M | $-20.1M | $-47.1M |
| Capital Expenditures | $605.0K | $1.3M | $121.0K | $111.0K |
| Cash from Investing | $12.6M | $46.2M | $-69.8M | $48.4M |
| Cash from Financing | $72.9M | $26.7M | $74.5M | $-5.9M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $17.9M | $-5.4M | $-15.3M | $-4.6M |
| Beginning Cash | $27.3M | $45.3M | $39.9M | $24.6M |
| Ending Cash | $45.3M | $39.9M | $24.6M | $20.0M |
Frequently Asked Questions
How does Aclaris Therapeutics, Inc. make money?
Oncology Drug Discovery focusing on ADC platform development, Collaborative Partnerships generating revenue from licensing deals and milestone payments, Preclinical Research utilizing internal R&D resources, and Commercialization preparation for future product launches.
What are the main risks for ACRS?
Significant operating losses due to high R&D expenditures totaling $52.6M in the latest fiscal year, Heavy reliance on external funding given a retained earnings deficit of $967.8M, Declining revenue trend from $29.8M in 2022 down to $7.8M currently, Regulatory uncertainty surrounding approval of novel oncology therapies.
What is ACRS's competitive advantage?
Proprietary antibody-drug conjugate technology platform targeting solid tumors, Established track record of successful partnerships with major pharmaceutical companies, Efficient cash management enabling extended runway despite current cash burn.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.